Aims We conducted a national survey to clarify the characteristics and clinical course of type 1 diabetes related to antiprogrammed cell death-1 therapy. Methods We analyzed the detailed data of 22 patients that were collected using a Japan Diabetes Society survey and a literature database search. Results Among the 22 patients, 11 (50.0%) met the criteria for fulminant type 1 diabetes and 11 (50.0%) met the criteria for acute-onset type 1 diabetes. The average patient age was 63 years. The mean duration between the date of the first anti-PD-1 antibody injection and development of type 1 diabetes was 155 days and ranged from 13 to 504 days. Flu-like symptoms, abdominal symptoms, and drowsiness were observed in 27.8, 31.6, and 16.7% patients, respectively. Mean ± standard deviation or median (first quartile-third quartile) glucose levels, HbA1c levels, urinary C-peptide immunoreactivity levels, and fasting serum C-peptide immunoreactivity levels were 617 ± 248 mg/dl, 8.1 ± 1.3%, 4.1 (1.4-9.4) μg/day, and 0.46 (0.20-0.70) ng/ml, respectively. Seventeen of 20 patients (85.0%) developed ketosis, and 7 of 18 patients (38.9%) developed diabetic ketoacidosis. Ten of 19 patients (52.6%) showed at least one elevated pancreatic enzyme level at the onset and two of seven patients showed this elevation before diabetes onset. Only one of 21 patients was anti-glutamic acid decarboxylase antibody positive. Conclusions Anti-programmed cell death-1 antibody-related type 1 diabetes varies from typical fulminant type 1 diabetes to acute-onset type 1 diabetes. However, diabetic ketoacidosis was frequently observed at the onset of diabetes. An appropriate diagnosis and treatment should be provided to avoid life-threatening metabolic alterations.
Introduction
Type 1 diabetes is a disease that is characterized by the destruction of pancreatic beta cells, which leads to a deficiency in insulin secretion. Most patients with type 1 diabetes have an immunological component of their disease pathogenesis, such as autoantibodies or genetic associations with genes controlling immune responses [1] . Besides autoimmune type 1 diabetes patients, there are many fulminant type 1 diabetes patients in Japan and other East Asian countries. Fulminant type 1 diabetes is a severe subtype of type 1 diabetes that was discovered in Japan and characterized by extremely rapid progression of beta-cell destruction and severe ketoacidosis [2, 3] . Islet autoantibodies were usually negative in this category. Some patients with severe fulminant type 1 diabetes experienced cardiac arrest or sudden death [4] .
Immune-checkpoint inhibitors including anti-programmed cell death-1 (PD-1) antibodies such as nivolumab and pembrolizumab selectively block interaction with the PD-1 receptor on T cells and restore T cell activation and proliferation [5] . Thus, PD-1 antibodies induce an anti-tumor response, and recently, they have been approved for the treatment of many types of cancer, such as melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin's lymphoma, head and neck cancer, and stomach cancer in Japan and also for urothelial carcinoma, colorectal cancer, and hepatocellular carcinoma in addition to above cancers in Western countries. However, as the use of immune-checkpoint inhibitors increases, the incidence of autoimmune side effects, which are called immune-related adverse events (irAE), is expected to increase. Interstitial pneumonia, colitis, hypothyroidism, hepatitis, skin rash, vitiligo, myasthenia gravis, neuropathy, myositis, uveitis, and type 1 diabetes are known autoimmune side effects [6] . Among them, type 1 diabetes is a severe side effect, because it progresses rapidly, often presents as ketoacidosis, and would be fatal without appropriate treatment [7] . Some patients with diabetes associated with anti-PD-1 antibodies meet the criteria for fulminant type 1 diabetes, and need prompt diagnosis and treatment. Fulminant type 1 diabetes has mainly been reported in East Asia and it accounts for approximately 20% of type 1 diabetes cases with a classical acute-onset pattern in Japan [8] . Thus, it is important to clarify the clinical characteristics of patients who developed anti-PD-1 antibody-related type 1 diabetes, including the classification of this clinical subtype, in Japan.
All nivolumab-induced adverse events were collected and they were publicly available in the safety databases created by Ono Pharmaceutical Company and Bristol-Myers Squibb [9] , and all pembrolizumab-induced adverse events were also collected by MSD [10] . The diagnosis of adverse events and classification of type 1 diabetes or fulminant type 1 diabetes was provided by the patients' attending doctors. According to the safety database, 20,600 patients were treated with nivolumab from July 4, 2014 to August 15, 2017 in Japan, and 67 patients (0.33%) developed "type 1 diabetes" or "fulminant type 1 diabetes". Among them, 40 patients (0.19%) were reported as having type 1 diabetes (10 patients had melanoma, 24 patients had non-small cell lung cancer, three patients had renal cell carcinoma, and the diagnosis for three patients was unknown) and 27 patients (0.13%) were reported to have fulminant type 1 diabetes (14 patients had melanoma, 12 patients had non-small cell lung cancer, and the diagnosis for one patient was unknown). Similarly, 3,603 patients were treated with pembrolizumab from December 19, 2016 to August 14, 2017 in Japan, and five patients (0.14%) developed "type 1 diabetes" or "fulminant type 1 diabetes". Among them, four patients (0.11%) were reported as having type 1 diabetes (one patient had melanoma, three patients had non-small cell lung cancer) and one patient (0.03%) was reported as having fulminant type 1 diabetes (non-small cell lung cancer). In the Ehime Study, a regional survey of type 1 diabetes in Japan and nine fulminant type 1 diabetes patients were observed out of 4980 diabetic patients and the frequency of fulminant type 1 diabetes in the general Japanese population was estimated to be 0.01% [11] . Therefore, incidence rates of type 1 diabetes related to nivolumab and pembrolizumab are 33 and 14 times higher than that of typical fulminant type 1 diabetes, respectively. In addition, there was no particular relationship between primary tumors and developed anti-PD-1 antibodyrelated type 1 diabetes. These results confirm that the blockade of binding between PD-1 and PD-L1 molecules by the anti-PD-1 antibody, not by a particular medicine, causes anti-PD-1 antibody-related type 1 diabetes.
There are patients who were reported to develop "fulminant type 1 diabetes" or "type 1 diabetes". However, there are too few of these case reports to reveal the entire clinical picture. In addition, type 1 diabetes, including fulminant type 1 diabetes, has racial differences in frequency and feature. Therefore, the Japanese analysis to clarify the characteristics and clinical course of anti-PD1 antibody-related type 1 diabetes is required.
In this study, we conducted a literature search and a national survey among the Japan Diabetes Society (JDS) members to collect data from patients who developed anti-PD-1 antibody-related type 1 diabetes. In addition to the 10 reported cases, we found an additional 12 unpublished cases. We have clarified the detailed characteristics and the clinical course in these 22 patients.
Methods
This study was performed under the auspices of the Japan Diabetes Society (JDS).
We conducted a national survey among JDS members and they reported information about patients who developed type 1 diabetes after anti-PD-1 therapy. We also performed a literature search using the key words "nivolumab", "pembrolizumab", "type 1 diabetes", and/or "PD-1" in PubMed and Ichushi (a Japanese article database) to identify articles published up to August 31, 2017 that described patients who developed type 1 diabetes after anti-PD-1 therapy. A questionnaire survey was administered to the members of the JDS and authors of the articles, and data from 22 patients were analyzed. The questionnaire included information on age, sex, primary tumor, metastasis, past history, family history, date of diabetes onset, flu-like symptom, digestive symptoms, hyperglycemic symptoms, consciousness, weight reduction, or other complications with or without drug withdrawal, and pancreatic imaging findings. We also examined body size measurements, laboratory findings, and islet autoantibodies, which were determined at 1 month before onset, the day of onset, and 1 month after onset at each hospital. The onset date is defined as the day that patients were diagnosed with anti-PD-1 antibody-related type 1 diabetes and their doctors started treatment for diabetes. As a reference value, we used data from elderly onset fulminant type 1 diabetes patients (their age range was 54-80 years) who had already registered to the database created by the JDS Committee on Type 1 Diabetes Mellitus Research, and whose data had been reported by the committee of the JDS between July 15, 2000 and June 30, 2006 [12] .
Diagnosis of acute-onset type 1 diabetes was made based on the criteria set by the Committee of the JDS [13] . Briefly, among patients who developed diabetic ketosis or ketoacidosis within 3 months after the onset of hyperglycemic symptoms and who needed insulin treatment continuously after their diabetes diagnosis, patients with islet autoantibodies are diagnosed with "acute-onset type 1 diabetes (autoimmune)", and those whose endogenous insulin secretion is depleted (fasting serum C-peptide immunoreactivity < 0.6 ng/ml) without verifiable islet autoantibodies are diagnosed with "acute-onset type 1 diabetes". Both diagnoses are called acute-onset type 1 diabetes in this study. A diagnosis of fulminant type 1 diabetes was based on the following criteria from the Report of the JDS Committee on type 1 diabetes mellitus research: (1) ketosis or ketoacidosis within 1 week after the onset of hyperglycemic symptoms; (2) urinary C-peptide below 10 μg/day or fasting serum C-peptide below 0.3 ng/ml and serum C-peptide below 0.5 ng/ml after glucagon injection or meal load soon after the onset of disease; and (3) plasma glucose (PG) level above 288 mg/dl and HbA1c below 8.7% at the first visit [14, 15] . To diagnose the patient's clinical entity, we used the lowest serum C-peptide value within 2 weeks after their onset of anti-PD-1 antibody-related type 1 diabetes, because duration of the disease before the start of insulin treatment can be 1-2 weeks for the development of fulminant type 1 diabetes. Diagnosis of diabetic ketoacidosis was based on criteria from the American Diabetes Association [16] .
The value of HbA1c (%) was estimated as a National Glycohemoglobin Standardization Program (NGSP) equivalent value, which was calculated using the formula reported by the Committee of the JDS [17] .
Values are expressed as the mean ± standard deviation (SD).
Results

Analysis of 22 patients with anti-PD-1 antibody-related type 1 diabetes
We analyzed data from 22 Japanese patients with anti-PD-1 antibody-related type 1 diabetes. Among them, 10 patients had been already reported as case reports [18] [19] [20] [21] [22] [23] [24] [25] [26] . Of the 22 patients, 11 (50.0%) met the criteria for fulminant type 1 diabetes [14, 15] , 11 (50.0%) met the criteria for acuteonset type 1 diabetes [13] . Although patients who met the criteria for fulminant type 1 diabetes exhibited comparable plasma glucose levels with those who met the criteria for acute-onset type 1 diabetes (642 ± 263 vs. 597 ± 246 mg/dl, respectively, P = 0.90), they tended to show lower HbA1c (7.4 ± 0.8 vs. 8.7 ± 1.4%, respectively, P = 0.42). All patients were reported to have developed type 1 diabetes after nivolumab treatment.
Background, clinical, and biological characteristics of anti-PD-1 antibody-related type 1 diabetes
The medical history of malignancy for the 22 patients is shown in Table 1 . Among these 22 patients, eight (36.4%) had melanoma, 10 (45.5%) had non-small cell lung cancer, two (9.1%) had renal cell carcinoma, one (4.5%) had Hodgkin's lymphoma, and one (4.5%) had breast cancer (off-label use). No patient had pancreatic metastasis. One breast cancer patient underwent four courses of pembrolizumab (PD-1 therapy) 196 days before nivolumab treatment [20] , and one lung cancer patient received 10 courses of durvalumab (programmed cell death ligand-1, PD-L1 antibody) 128 days before nivolumab treatment. The rate of adverse events reported for the patients in this study was consistent with the adverse event rate in the safety databases.
Clinical and biological characteristics of 22 anti-PD-1 antibody-related type 1 diabetes patients are shown in The mean duration between the date of the first anti-PD-1 antibody injection and development of type 1 diabetes was 155 ± 123 days, ranging from 13 to 504 days. The distribution of the period is shown in Fig. 1 . All reported patients continued to receive insulin therapy (data for five patients are unknown) 1 month after the development of type 1 diabetes. Of 22 patients, one patient continued nivolumab treatment after the development of type 1 diabetes, eight patients stopped, and nine patients interrupted their treatments for 7-44 days before restarting.
The changes in patients' serum C-peptide levels after they were diagnosed with diabetes are shown in Fig. 2 . All data were measured before they restarted anti-PD-1 antibody treatment. For most patients, their serum C-peptide levels decreased over a period of 2-3 weeks after the development of diabetes. In three patients, whose serum C-peptide levels were maintained to some extent, one patient's serum C-peptide level was increased 1 week after stopping nivolumab, and two patients' C-peptide levels tended to increase 2-3 weeks after stopping nivolumab. One of them (noted by an asterisk) received steroid injections as a part of the chemotherapy at 21-23 days after the development of type 1 diabetes. The changes of serum C-peptide levels after restarting anti-PD-1 antibody treatment could not be analyzed because of a lack of information.
Discussion
In the present study, which was conducted in Japan, we clarified the characteristics of anti-PD-1 antibody-related type 1 diabetes, regarding the clinical symptoms, status of islet antibodies, and clinical entity as a subtype of (type 1) diabetes. A national survey among JDS members was effective in collecting and analyzing unpublished cases. For clinical symptoms, patients with anti-PD-1 antibody-related type 1 diabetes were generally less likely to show abdominal symptoms and drowsiness compared with patients with fulminant type 1 diabetes patients. This might be because of the milder onset of anti-PD-1 antibody-related type 1 diabetes compared with fulminant type 1 diabetes. In addition, our patients were less likely to show flu-like symptoms compared with fulminant type 1 diabetes patients. Seventy-two percent of typical fulminant type 1 diabetes patients had a history of flu-like symptoms before onset, and anti-enterovirus, anti-human herpesvirus 6, and anticytomegalovirus antibody levels are reported to increase in some patients [8, 27] . Most patients, except one who showed elevated cytomegalovirus antibodies, showed negative symptoms and blood examination results for an acute viral infection in this study. We can speculate that injection of anti-PD-1 antibody activates T cells instead of a viral infection activating these cells, and the activated T cells, particularly in patients whose T cells tended to attack their pancreatic beta cells, may destroy beta cells to contribute to development of type 1 diabetes.
For islet autoantibodies, only one patient was positive for anti-GAD-antibody, and no patients were positive for any other antibodies. Of the 24 anti-PD-1 antibody-related type 1 diabetes patients including Japanese and Westerners (six Japanese patients were also included in our study), 50% of them were positive for islet autoantibodies and almost all of the positive patients were Western patients [28] . Considering that fulminant type 1 diabetes develops mainly in East Asia and rarely in Western countries [3] , it is possible that there is a difference in pathogenesis between Asian patients who develop anti-PD-1 antibody-related type 1 diabetes without islet autoantibodies and Western patients with antibodies or that a difference in the human leukocyte antigen (HLA) genotypes between Asian and Western patients influences the tendency to produce antibodies. Because few detailed data are available on the incidence of anti-PD-1 antibodyrelated type 1 diabetes in Western countries [29] , and the data on HLA were not enough to evaluate also in this study, further data accumulation is recommended.
Among our anti-PD-1 antibody-related type 1 diabetes patients, we found that 50.0% of the patients fulfilled the criteria of fulminant type 1 diabetes in the national survey. Because patients visited their clinics regularly for their cancer treatment in every 2-3 weeks, it was possible to detect the development of diabetes earlier than ordinary fulminant type 1 diabetes. In addition, the diagnostic criteria of fulminant type 1 diabetes reported that the duration between the onset of hyperglycemic symptoms and ketosis or ketoacidosis is usually within 1 week but sometimes between 1 to 2 weeks. Therefore, we used the lowest serum C-peptide level within 2 weeks after the onset of anti-PD-1 antibodyrelated type 1 diabetes to diagnose their clinical entity.
Among patients who were diagnosed with acute-onset type 1 diabetes, one patient's serum C-peptide was exhausted 18 days after the onset of diabetes. The prevalence of subtypes within PD-1 antibody-related type 1 diabetes might change by timing when serum C-peptide is measured, and further study is needed, because there is not enough information on subsequent serum C-peptide levels. In this study, patients' arterial pH and HbA1c levels at onset tended to be higher compared with that of elderly onset fulminant type 1 diabetes patients, and plasma glucose levels were lower than in the elderly onset fulminant type 1 diabetes patients [12] , suggesting that anti-PD-1 antibody-related type 1 diabetes develops somewhat less rapidly compared with typical fulminant type 1 diabetes. However, the patients' plasma glucose levels at disease onset (overall, 617 ± 248 mg/dl) were higher than that of acute-onset type 1 diabetes patients in Japan (434 ± 213 mg/dl) [8] and type 1 diabetes patients in Western countries [385 (95% confidence interval, CI 371-401) mg/dl] [30] . Moreover, our patients frequently developed diabetic ketoacidosis (38.9%) at the onset, which is higher than the incidence rate of diabetic ketoacidosis at the onset of type 1 diabetes in Germany and Austria (21.1%) [31] . Although their mean serum C-peptide level at the onset, 0.46 (0.20-0.70) ng/ml, is almost the same as that of both acute-onset type 1 diabetes patients in Japan [13] and type 1 diabetes in the United States [32] , the insulinsecreting capacity in most of the patients was exhausted in about 2-3 weeks after disease development, which is slower than in patients with fulminant type 1 diabetes but faster than in both patients with acute-onset type 1 diabetes in Japan [13] and those with type 1 diabetes in the Unites States [33] . These results suggest that the speed of the progression of beta-cell destruction related to anti-PD-1 antibody treatment is slower than fulminant type 1 diabetes but faster than acute-onset type 1 diabetes in Japan. Based on the above-mentioned results and considering many differences in characteristics between anti-PD-1 antibody-related type 1 diabetes and typical fulminant or acute-onset type 1 diabetes, it would be appropriate to consider anti-PD-1 antibody-related type 1 diabetes as a distinct entity and to introduce a newly coined name for this entity. We suggest 'anti-PD-1 antibody-related (type 1) diabetes' as an appropriate name for this entity. This subtype may be classified in type 1 diabetes or "other specific types of diabetes".
The JDS recommends to check patients' plasma glucose levels at every visit (2-3 weeks), and the American society of Clinical Oncology recommends to measure glucose levels with each treatment cycle during induction for 12 weeks, then every 3-6 weeks thereafter [34] . The speed of the progression of beta-cell destruction in this study can support this recommendation. In addition, the result of this study revealed that most patients developed anti-PD-1 antibodyrelated type 1 diabetes within 7 months from the first dose of anti-PD-1 antibody, and we suggest that careful monitoring of plasma glucose levels should be delivered especially during these 7 months. However, anti-PD-1 antibody-related (type 1) diabetes has a broad disease spectrum. Patients can present with both fulminant type 1 diabetes and acute-onset type 1 diabetes. Because we could not analyze the factor that causes severe disease presentation or death because of the lack of information, further study is needed.
Another exceptional result is that in three patients, the serum C-peptide level tended to increase after withdrawal of anti-PD-1 therapy [23, 24, 26] . However, in many other patients, the serum C-peptide levels were either undetectable from the beginning or declined and became undetectable (data not shown) [18, 22, 28] . Because the three patients' serum C-peptide levels were maintained to some extent, prompt diagnosis and treatment might contribute to avoiding complete exhaustion of insulin secretion. Moreover, 10 of 19 patients (52.6%) showed at least one elevated exocrine pancreatic enzyme result at the onset of type 1 diabetes and two of seven patients (28.6%) showed elevated exocrine pancreatic enzyme levels 1 month before onset. Careful monitoring of exocrine pancreatic enzyme levels may contribute to early detection of the development of beta-cell destruction in anti-PD-1 antibody-related type 1 diabetes.
As a limitation, in this study, we excluded cases of anti-PD1 antibody-related type 1 diabetes during the drug trials and it might cause a selection bias. In addition, significant differences in Table 2 should be regarded only as a guide, because the period and method of collecting patients are different between two studies and there seems to be some bias. In addition, we analyzed mainly the data for anti-PD-1 antibody-related type 1 diabetes at the onset and before and after 1 month. Future follow-up and analysis of the resulting long-term data are recommended.
In conclusion, we found that anti-PD-1 antibody-related type 1 diabetes varied from typical fulminant type 1 diabetes to acute-onset type 1 diabetes, but diabetic ketoacidosis was frequently observed at the onset of diabetes. An appropriate diagnosis and treatment should be provided to avoid lifethreatening metabolic alterations.
